| Date:             | June 29 th, 2022_  |  |
|-------------------|--------------------|--|
| Your <u>Name:</u> | Yangyun Wang       |  |
| Manuscript Title: | Efficacy of Yun-ty | pe pelvic floor optimal training therapy and PFMT on middle aged |
| women with mild   | to moderate overad | tive bladder: a randomized controlled trial                      |
| Manuscript numb   | er (if known):     |  |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

|   |                               | Name all entities with<br>whom you have this<br>relationship or indicate<br>none (add rows as<br>needed) | Specifications/Comments<br>(e.g., if payments were made to you or to your<br>institution) |
|---|-------------------------------|--|---|
|   |                               | Time frame: Since the initial  | planning of the work  |
| 1 | All support for the present   | _XNone   |   |
|   | manuscript (e.g., funding,    |  |   |
|   | provision of study materials, |  |   |
|   | medical writing, article      |  |   |
|   | processing charges, etc.)     |  |   |
|   | No time limit for this item.  |  |   |
|   |                               |  |   |
|   |                               |  |   |
|   |                               | Time frame: past   | 36 months   |
| 2 | Grants or contracts from      | _XNone   |   |
|   | any entity (if not indicated  |  |   |
|   | in item #1 above).            |  |   |
| 3 | Royalties or licenses         | _XNone   |   |
|   |                               |  |   |
|   |                               |  |   |
| 4 | Consulting fees               | _XNone   |   |
|   |                               |  |   |

| 5  | 5 Payment or honoraria for lectures, presentations, | _XNone |  |
|----|---|--------|--|
|    |   |        |  |
|    | speakers bureaus,                                   |        |  |
|    | manuscript writing or                               |        |  |
|    | educational events                                  |        |  |
| 6  | Payment for expert                                  | _XNone |  |
|    | testimony   |        |  |
| _  |   |        |  |
| 7  | Support for attending meetings and/or travel        | _XNone |  |
|    |   |        |  |
|    |   |        |  |
| 8  | Patents planned, issued or                          | _XNone |  |
|    | pending   |        |  |
|    |   |        |  |
| 9  | Participation on a Data                             | _XNone |  |
|    | Safety Monitoring Board or                          |        |  |
|    | Advisory Board                                      |        |  |
| 10 | Leadership or fiduciary role                        | XNone  |  |
|    | in other board, society,                            |        |  |
|    | committee or advocacy                               |        |  |
|    | group, paid or unpaid                               | X N    |  |
| 11 | Stock or stock options                              | _XNone |  |
|    |   |        |  |
| 12 | Possint of aquinment                                | X None |  |
| 12 | Receipt of equipment,<br>materials, drugs, medical  | _XNone |  |
|    | writing, gifts or other                             |        |  |
|    | services  |        |  |
| 13 | Other financial or non-                             | _XNone |  |
|    | financial interests                                 |        |  |
|    |   |        |  |

The author has no conflicts of interest to declare.

Please place an "X" next to the following statement to indicate your agreement:

| Date:                         | _June 29 th, 2022  |  |  |  |
|-------------------------------|--|--|--|--|
| Your Name:                    | Chaoliang Shi  |  |  |  |
| Manuscript Title:             | Efficacy of Yun-type pelvic floor optimal training therapy and PFMT on middle aged |  |  |  |
| women with mild to            | moderate overactive bladder: a randomized controlled trial                         |  |  |  |
| Manuscript number (if known): |  |  |  |  |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

|   |                               | Name all entities with<br>whom you have this<br>relationship or indicate<br>none (add rows as<br>needed) | Specifications/Comments<br>(e.g., if payments were made to you or to your<br>institution) |
|---|-------------------------------|--|---|
|   |                               | Time frame: Since the initial  | planning of the work  |
| 1 | All support for the present   | _XNone   |   |
|   | manuscript (e.g., funding,    |  |   |
|   | provision of study materials, |  |   |
|   | medical writing, article      |  |   |
|   | processing charges, etc.)     |  |   |
|   | No time limit for this item.  |  |   |
|   |                               |  |   |
|   |                               |  |   |
|   |                               | Time frame: past   | 36 months   |
| 2 | Grants or contracts from      | _XNone   |   |
|   | any entity (if not indicated  |  |   |
|   | in item #1 above).            |  |   |
| 3 | Royalties or licenses         | _XNone   |   |
|   |                               |  |   |
|   |                               |  |   |
| 4 | Consulting fees               | _XNone   |   |
|   |                               |  |   |

| 5  | 5 Payment or honoraria for lectures, presentations, | _XNone |  |
|----|---|--------|--|
|    |   |        |  |
|    | speakers bureaus,                                   |        |  |
|    | manuscript writing or                               |        |  |
|    | educational events                                  |        |  |
| 6  | Payment for expert                                  | _XNone |  |
|    | testimony   |        |  |
| _  |   |        |  |
| 7  | Support for attending meetings and/or travel        | _XNone |  |
|    |   |        |  |
|    |   |        |  |
| 8  | Patents planned, issued or                          | _XNone |  |
|    | pending   |        |  |
|    |   |        |  |
| 9  | Participation on a Data                             | _XNone |  |
|    | Safety Monitoring Board or                          |        |  |
|    | Advisory Board                                      |        |  |
| 10 | Leadership or fiduciary role                        | XNone  |  |
|    | in other board, society,                            |        |  |
|    | committee or advocacy                               |        |  |
|    | group, paid or unpaid                               | X N    |  |
| 11 | Stock or stock options                              | _XNone |  |
|    |   |        |  |
| 12 | Possint of aquinment                                | X None |  |
| 12 | Receipt of equipment,<br>materials, drugs, medical  | _XNone |  |
|    | writing, gifts or other                             |        |  |
|    | services  |        |  |
| 13 | Other financial or non-                             | _XNone |  |
|    | financial interests                                 |        |  |
|    |   |        |  |

The author has no conflicts of interest to declare.

Please place an "X" next to the following statement to indicate your agreement:

| Date:                 | _June 29 th, 2022  |
|-----------------------|--|
| Your Name:            | Jiawei Wang  |
| Manuscript Title:     | Efficacy of Yun-type pelvic floor optimal training therapy and PFMT on middle aged women wit |
| mild to moderate over | eractive bladder: a randomized controlled trial  |
| Manuscript numbe      | r (if known):  |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

|   |  | Name all entities with<br>whom you have this<br>relationship or indicate<br>none (add rows as<br>needed) | Specifications/Comments<br>(e.g., if payments were made to you or to your<br>institution) |
|---|--|--|---|
|   |  | Time frame: Since the initial  | planning of the work  |
| 1 | All support for the present<br>manuscript (e.g., funding,<br>provision of study materials, | _XNone   |   |
|   | medical writing, article   |  |   |
|   | processing charges, etc.)<br>No time limit for this item.                                  |  |   |
|   | No time mint for this item.  |  |   |
|   |  |  |   |
|   |  | Time frame: past   | 36 months   |
| 2 | Grants or contracts from<br>any entity (if not indicated<br>in item #1 above).             | _XNone   |   |
| 3 | Royalties or licenses  | _XNone   |   |
|   |  |  |   |
| 4 | Consulting fees  | _XNone   |   |

| 5  | Payment or honoraria for                           | _XNone |  |
|----|--|--------|--|
|    | lectures, presentations,                           |        |  |
|    | speakers bureaus,                                  |        |  |
|    | manuscript writing or                              |        |  |
|    | educational events                                 |        |  |
| 6  | Payment for expert                                 | _XNone |  |
|    | testimony  |        |  |
|    |  |        |  |
| 7  | Support for attending<br>meetings and/or travel    | _XNone |  |
|    |  |        |  |
|    |  |        |  |
| 8  | Patents planned, issued or                         | _XNone |  |
|    | pending  |        |  |
|    |  |        |  |
| 9  | 9 Participation on a Data                          | _XNone |  |
|    | Safety Monitoring Board or                         |        |  |
|    | Advisory Board                                     |        |  |
| 10 | 10 Leadership or fiduciary role                    | _XNone |  |
|    | in other board, society,                           |        |  |
|    | committee or advocacy                              |        |  |
|    | group, paid or unpaid                              |        |  |
| 11 | Stock or stock options                             | _XNone |  |
|    |  |        |  |
| 12 |  | X N    |  |
| 12 | Receipt of equipment,<br>materials, drugs, medical | _XNone |  |
|    | writing, gifts or other                            |        |  |
|    | services   |        |  |
| 13 | Other financial or non-                            | _XNone |  |
|    | financial interests                                |        |  |
|    |  |        |  |

The author has no conflicts of interest to declare.

Please place an "X" next to the following statement to indicate your agreement:

| Date:                         | _June 29 th, 2022  |  |  |  |
|-------------------------------|--|--|--|--|
| Your Name:                    | Guowei Shi   |  |  |  |
| Manuscript Title:             | Efficacy of Yun-type pelvic floor optimal training therapy and PFMT on middle aged |  |  |  |
| women with mild to            | o moderate overactive bladder: a randomized controlled trial                       |  |  |  |
| Manuscript number (if known): |  |  |  |  |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

|   |                               | Name all entities with<br>whom you have this<br>relationship or indicate<br>none (add rows as<br>needed) | Specifications/Comments<br>(e.g., if payments were made to you or to your<br>institution) |
|---|-------------------------------|--|---|
|   |                               | Time frame: Since the initial  | planning of the work  |
| 1 | All support for the present   | _XNone   |   |
|   | manuscript (e.g., funding,    |  |   |
|   | provision of study materials, |  |   |
|   | medical writing, article      |  |   |
|   | processing charges, etc.)     |  |   |
|   | No time limit for this item.  |  |   |
|   |                               |  |   |
|   |                               |  |   |
|   |                               | Time frame: past   | 36 months   |
| 2 | Grants or contracts from      | _XNone   |   |
|   | any entity (if not indicated  |  |   |
|   | in item #1 above).            |  |   |
| 3 | Royalties or licenses         | _XNone   |   |
|   |                               |  |   |
|   |                               |  |   |
| 4 | Consulting fees               | _XNone   |   |
|   |                               |  |   |

| 5  | 5 Payment or honoraria for lectures, presentations, | _XNone |  |
|----|---|--------|--|
|    |   |        |  |
|    | speakers bureaus,                                   |        |  |
|    | manuscript writing or                               |        |  |
|    | educational events                                  |        |  |
| 6  | Payment for expert                                  | _XNone |  |
|    | testimony   |        |  |
| _  |   |        |  |
| 7  | Support for attending meetings and/or travel        | _XNone |  |
|    |   |        |  |
|    |   |        |  |
| 8  | Patents planned, issued or                          | _XNone |  |
|    | pending   |        |  |
|    |   |        |  |
| 9  | Participation on a Data                             | _XNone |  |
|    | Safety Monitoring Board or                          |        |  |
|    | Advisory Board                                      |        |  |
| 10 | Leadership or fiduciary role                        | XNone  |  |
|    | in other board, society,                            |        |  |
|    | committee or advocacy                               |        |  |
|    | group, paid or unpaid                               | X N    |  |
| 11 | Stock or stock options                              | _XNone |  |
|    |   |        |  |
| 12 | Possint of aquinment                                | X None |  |
| 12 | Receipt of equipment,<br>materials, drugs, medical  | _XNone |  |
|    | writing, gifts or other                             |        |  |
|    | services  |        |  |
| 13 | Other financial or non-                             | _XNone |  |
|    | financial interests                                 |        |  |
|    |   |        |  |

The author has no conflicts of interest to declare.

Please place an "X" next to the following statement to indicate your agreement: